# Johnson & Johnson acquires Firefly Bio in oncology platform deal

> ma · REPORTED · 2026-06-21

Johnson & Johnson announced the acquisition of Firefly Bio, an oncology-focused biotech, adding a targeted cancer therapy platform to J&J's growing oncology franchise. The deal was flagged alongside GSK-Nuvalent and Roche-Nurix as evidence of sustained industry appetite for clinically validated targeted oncology modalities in 2026.

- Company: Johnson & Johnson / Firefly Bio
- Sector: oncology
- Primary source: https://www.pharmexec.com/view/roundup-ipsen-acquire-kartos-therapeutics-zymeworks-theravance-biopharma

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.